Get all your news in one place.
100's of premium titles.
One app.
Start reading
MarketBeat
MarketBeat
Business
Chris Markoch

Novartis' Moonshot Cancer Therapy Could Be Future Growth Driver

GLP-1 drugs are taking much oxygen out of the biotechnology trade. However, many investors have been eyeing other areas in the sector, particularly cancer research. Novartis AG (NYSE: NVS) is up over 31% in 2025, and a novel cancer treatment could give the Swiss company a long runway for growth.

A Moonshot That Is Radioactive

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.